Tokyo Tape
Sign in
← M3

Quarterly report · Q1

2413.TEDINET S100RK8S
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥57.4bn2023-04-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥57.0bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Operating income¥18.0bn2023-04-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥18.7bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Profit before tax¥19.8bn2023-04-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥19.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥12.4bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥12.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥13.6bn2023-04-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥13.5bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Total assets¥439.6bnat 2023-06-30Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥357.5bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥110.9bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥328.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥275.1bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥316.8bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥268.8bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥130.7bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.8bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥12.0bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥9.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥18.2bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥14.7bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥16.4bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥12.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥18.292023-04-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥17.862022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥18.272023-04-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥17.852022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.2%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥167m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥16m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥6.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥114m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥1.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-06-30¥21.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-06-30¥21.1bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥868m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-06-30¥8.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥11m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-06-30¥3.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥831m
—segment totalrevenue2023-04-01 → 2023-06-30¥57.9bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥56.9bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥1.0bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥18.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥471m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥5.2bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥267m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥7.2bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥162m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-06-30¥20.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-06-30¥19.3bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥951m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-06-30¥4.0bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥10.2bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.9bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥304m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.4bn
—segment totalrevenue2022-04-01 → 2022-06-30¥58.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥56.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥1.7bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥19.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 587
ItemContextValueUnit
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember192912000000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember257840000000JPY
Equity IFRSPrior2YearInstant_NonControllingInterestsIFRSMember6113000000JPY
Equity IFRSPrior2YearInstant263954000000JPY
Profit loss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember12127000000JPY
Profit loss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember12127000000JPY
Profit loss IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember1360000000JPY
Profit loss IFRSPrior1YTDDuration13487000000JPY
Other comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember9565000000JPY
Other comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember9565000000JPY
Other comprehensive income IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember208000000JPY
Other comprehensive income IFRSPrior1YTDDuration9773000000JPY
Comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember9565000000JPY
Comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember12127000000JPY
Comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember21692000000JPY
Comprehensive income IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember1568000000JPY
Comprehensive income IFRSPrior1YTDDuration23261000000JPY
Dividends ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-10862000000JPY
Dividends ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-10862000000JPY
Dividends ss IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember-1790000000JPY
Dividends ss IFRSPrior1YTDDuration-12651000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember12000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember12000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember79000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember103000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration103000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember-58000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember58000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration－JPY
Other ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Other ss IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember385000000JPY
Other ss IFRSPrior1YTDDuration385000000JPY
Total transactions with owners IFRSPrior1YTDDuration_ShareCapitalIFRSMember12000000JPY
Total transactions with owners IFRSPrior1YTDDuration_CapitalSurplusIFRSMember12000000JPY
Total transactions with owners IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Total transactions with owners IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember21000000JPY
Total transactions with owners IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-10804000000JPY
Total transactions with owners IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-10759000000JPY
Total transactions with owners IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember-1405000000JPY
Total transactions with owners IFRSPrior1YTDDuration-12163000000JPY
Equity IFRSPrior1QuarterInstant_ShareCapitalIFRSMember29141000000JPY
Equity IFRSPrior1QuarterInstant_CapitalSurplusIFRSMember29716000000JPY
Equity IFRSPrior1QuarterInstant_TreasurySharesIFRSMember-36000000JPY
Equity IFRSPrior1QuarterInstant_OtherComponentsOfEquityIFRSMember15718000000JPY
Equity IFRSPrior1QuarterInstant_RetainedEarningsIFRSMember194236000000JPY
Equity IFRSPrior1QuarterInstant_EquityAttributableToOwnersOfParentIFRSMember268774000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass